Journal article

The Effect of Substance Use on 10-Year Outcome in First-Episode Psychosis

Melissa A Weibell, Wenche ten Velden Hegelstad, Bjorn Auestad, Jorgen Bramness, Julie Evensen, Ulrik Haahr, Inge Joa, Jan Olav Johannessen, Tor Ketil Larsen, Ingrid Melle, Stein Opjordsmoen, Bjorn Rishovd Rund, Erik Simonsen, Per Vaglum, Thomas McGlashan, Patrick McGorry, Svein Friis

SCHIZOPHRENIA BULLETIN | OXFORD UNIV PRESS | Published : 2017

Abstract

Substance use is common in first-episode psychosis (FEP) and has been linked to poorer outcomes with more severe psychopathology and higher relapse rates. Early substance discontinuation appears to improve symptoms and function. However, studies vary widely in their methodology, and few have examined patients longitudinally, making it difficult to draw conclusions for practice and treatment. We aimed to investigate the relationship between substance use and early abstinence and the long-term course of illness in a representative sample of FEP patients. Out of 301 included patients, 266 could be divided into 4 groups based on substance use patterns during the first 2 years of treatment: persi..

View full abstract

Grants

Awarded by Health West, Norway


Awarded by Norwegian National Research Council


Awarded by National Council for Mental Health, Health and Rehabilitation


Awarded by NIM


Awarded by Health South East


Awarded by Health West


Funding Acknowledgements

This work was supported by Health West, Norway #911369; the Norwegian National Research Council #133897/320 and #154642/320, the Norwegian Department of Health and Social Affairs, and the National Council for Mental Health, Health and Rehabilitation #1997/41 and #2002/306, Rogaland County and Oslo County. This work was also funded by the Theodore and Vada Stanley Foundation and the Regional Health Research Foundation for Eastern Region, Denmark; Roskilde County, Helsefonden, Lundbeck Pharma, Eli Lily, and Janssen Cilag Pharmaceuticals Denmark; the National Alliance for Research on Schizophrenia and Depression (NARSAD) distinguished investigator award and NIM grant MH-01654 and a NARSAD young investigator award; and Health South East #2008001 and Health West #200202797-65 and #911313.